Endometrial Cancer GOG 229L
March 13, 2013
Location: The Hospital of Central Connecticut
A Phase II Trial of AMG 386 (IND#111071), A Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients with Persistent/Recurrent Carcinoma of the Endometrium.